As part of the COVID-19 International Research Team, researchers at the Johns Hopkins Kimmel Cancer Center, Children’s Hospital of Philadelphia, the University of Pittsburgh and Weill Cornell Medicine discovered a novel cause of cytokine storm -; the extreme inflammatory response associated with increased risk of death in COVID-19 infection.
FDA Approves First Interchangeable Biosimilars to Aflibercept for AMD
The FDA approved the first interchangeable biosimilars to aflibercept (Eylea) to treat macular degeneration, according to an announcement from the agency. As interchangeable biosimilars, aflibercept-jbvf
May 21, 2024